San­doz opens two new fa­cil­i­ties; Gates Foun­da­tion funds nee­dle-free vac­cines; No­var­tis ex­pands Japan­ese site

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

San­doz in­au­gu­rat­ed two sep­a­rate fa­cil­i­ties in Aus­tria and Ger­many ded­i­cat­ed to the pro­duc­tion of peni­cillin and the de­vel­op­ment of biosim­i­lars, re­spec­tive­ly. The gener­ic drug­mak­er in­vest­ed €150 mil­lion ($163 mil­lion) in the Aus­tri­an site and €25 mil­lion ($27 mil­lion) in the Ger­man site. The open­ings “reaf­firm the dual San­doz com­mit­ment to en­sur­ing sus­tain­able ac­cess to qual­i­ty an­tibi­otics and spear­head­ing de­vel­op­ment of biosim­i­lars,” the com­pa­ny said in a Nov. 10 re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.